| Document |
Document Title |
|
WO/2007/041077A2 |
The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating RXR mediated disorders. More particularly, the compounds of the presen...
|
|
WO/2007/039736A1 |
The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
|
|
WO/2007/038243A1 |
The present invention provides a compounds the formula (IV): and methods for producing an α-(phenoxy)phenylacetic acid compound of the formula: wherein R1 is a member selected from the group consisting of: each R2 is a member independen...
|
|
WO/2007/037187A1 |
A sulfonamide derivative having DP receptor antagonistic activity; and a medicinal composition and a therapeutic agent for allergic diseases which each contains the compound as an active ingredient. The derivative is a compound represent...
|
|
WO/2007/036571A1 |
The invention relates to aldimines of formula (I), the resulting products thereof, in addition to the uses thereof. The compounds containing aldimines and aldimines are characterised in that they are odour-free and during hydrolysis sepa...
|
|
WO/2007/035425A2 |
Certain cyclopropyl amines are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.
|
|
WO2007005785B1 |
The present application provides novel thiazole derivatives that are useful as activators of Adenosine 5'-Monophosphate-Activated Protein Kinase and pharmaceutical compositions containing such compounds.
|
|
WO/2007/031698A1 |
The present invention provides a process comprising substitution of an acceptor molecule comprising a group -XC(O)- wherein X is O, S or NR8, where R8 is C1-6 alkyl, C6-12 aryl or hydrogen, with a nucleophile, wherein the acceptor molecu...
|
|
WO/2007/025709A2 |
The invention relates to novel diamines of the formula (I) in which all variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments ...
|
|
WO/2007/026753A1 |
Disclosed is a method for producing a 2-oxazoline analogue or a 1,3-oxazine analogue represented by the general formula (3) below wherein 1,2-aminoalcohol or 1,2-aminothiol is reacted with α,α-dihaloamine. (3) (In the formula, n is 0 o...
|
|
WO/2007/023056A1 |
The present invention relates to a process for the organo- catalysed kinetic racemate resolution of compounds of the general formula (II). It is thus possible through the action of catalytic amounts of enantiomerically enriched compounds...
|
|
WO/2007/020227A1 |
The invention relates to a method for producing betamimetics of formula (I), in which n represents 1 or 2; R1 represents hydrogen, halogen, C1-4 alkyl or O-C1-4 alkyl; R2 represents hydrogen, halogen, C1-4 alkyl or O-C1-4 alkyl, and; R3 ...
|
|
WO/2007/020954A1 |
Disclosed is a polymer compound containing a residue of a compound represented by the following formula (1). (In the formula, ring C1, ring C2 and ring C3 independently represent an aromatic hydrocarbon ring or a heterocyclic ring; A1 re...
|
|
WO/2007/017507A1 |
The invention relates to the substituted 1,2-ethylenediamines of general formula (I), wherein the groups R1 to R13, A, B, L and i are defined as in the description and the claims. The invention also relates to the use thereof in the trea...
|
|
WO/2007/018168A1 |
It is intended to provide a compound which can be used for preventing and/or treating a disease associated with 5HT2B receptor and 5HT7 receptor, particularly for treating irritable bowel syndrome (IBS) and/or preventing migraine. It was...
|
|
WO/2007/014462A1 |
This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressur...
|
|
WO/2007/012964A1 |
The present invention relates to a novel method for the optical resolution of racemic alkylpiperazinylphenyl compounds that include selective 5HTiD antagonists useful in treating or preventing depression, anxiety, migraine, obsessive com...
|
|
WO/2007/014154A2 |
10-Substituted tetracycline compounds are described.
|
|
WO/2007/012580A1 |
The invention relates to the use of tetrahydrobenzoxazines (I), where R1 = a hydrocarbon group and R2, R3, R4 and R5 independently = H, OH or hydrocarbon and R2 to R5 can also form a second and a third tetrahydrooxazine ring with the pro...
|
|
WO/2007/011065A2 |
The present invention relates to a production method of an optically active morpholine compound represented by the formula 10, which includes the following steps: wherein each symbol is as defined in the specification. The present invent...
|
|
WO/2007/011292A1 |
The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated d...
|
|
WO/2007/003965A1 |
The present invention relates to the compounds of formula (I): wherein A,B, n, X, Y, Z, R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them and ...
|
|
WO/2007/000628A1 |
The present invention relates to a novel quaternary ammonium salt useful as a potential intermediate in the preparation of amorolfine and its salt. Further the invention also relates to the preparation of the intermediate.
|
|
WO/2006/136073A1 |
N-carboxyl substituted benzoxazine compounds of formula (I) are disclosed Wherein, Het is formula (II) or formula (III) as follows: X is H, halogen, CN, or methyl; Y is O or NH; R1 is H, halogen, methyl or phenyl; R2 is (C1-C4) alkyl or ...
|
|
WO/2006/136461A2 |
The present invention relates to non-steroidal progesterone receptor modulators of the general formula (I), a process for their preparation, the use of the progesterone receptor modulators for producing medicaments, and pharmaceutical co...
|
|
WO/2006/134955A1 |
A compound represented by the general formula (1) or (100), a salt thereof or a hydrate of the compound or salt, which is excellent in cell adhesion-inhibitory effect and cell infiltration-inhibitory effect: (1) (100) wherein R10 represe...
|
|
WO/2006/128802A2 |
The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined hereinabove which are active at the GABAB receptor and which can be used for the preparation of medicaments useful in the control or preventio...
|
|
WO2006086705B1 |
The present invention relates to a series of substituted bis aryl and heteroaryl compounds of formula (I): Wherein X, Y, Z, A, B, D, Ar, R1 and R2 are as defined herein. The compounds of this invention are selective 5HT2A antagonists, an...
|
|
WO/2006/117743A1 |
The present invention relates to substituted aromatic compounds, which have PPAR modulating activity, and hence can be used as anti-diabetic agents. Compounds described herein can be used as peroxisome proliferation activated receptor (P...
|
|
WO/2006/116498A2 |
Micronized tanaproget, purified tanaproget Form I, and micronized, purified tanaproget Form I are provided. Also provided are compositions containing one or more of the prepared tanaproget forms, methods of using one or more of the prepa...
|
|
WO/2006/105127A2 |
Compounds, pharmaceutical compositions, kits and methods are provided for use with hydroxysteroid dehydrogenases that comprise a compound selected from the group consisting of: formula (I), wherein the variables are as defined herein.
|
|
WO/2006/101009A1 |
This invention provides a Nile red-based red luminescent compound, which, upon the application of electric energy, can emit light of red close to deep red with high brightness, and a luminescent element. The Nile red-based red luminescen...
|
|
WO2005064008A9 |
Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Composit...
|
|
WO/2006/094994A1 |
The invention relates to the use of 4-aminopyrimidines of formula (I), in which R1 = H, halogen, cyano, alkyl, alkylhalide, alkenyl, alkinyl, cycloalkyl, alkoxy, alkoxyalkyl, benzyloxyalkyl, alkoxyalkenyl or alkoxyalkinyl, R2 = H, haloge...
|
|
WO/2006/094236A1 |
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treatin and/or preventing a wide variety of diseases and disorders...
|
|
WO/2006/090235A1 |
The present invention relates to C ompounds having the structure of Formula I: wherein n is an integer from 1 to 5; R1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, arylox...
|
|
WO/2006/089859A1 |
The invention concerns the use of compounds of formula (I), wherein the radicals R1, R2 and R3 are such as defined in the description and the claims, for producing a drug for treating respiratory diseases as well as novel compounds of fo...
|
|
WO/2006/087935A1 |
A pharmaceutical composition, especially therapeutic and/or preventive pharmaceutical composition that has high therapeutic effect and selective toxicity on parasitic protozoa infections, exhibiting life-extending effectiveness, etc. The...
|
|
WO/2006/088720A2 |
This invention provides compounds of Formula (I); wherein: R1 is a moiety selected from the group: (II) and (III) n is an integer of 1 or 2; R2 is selected from hydrogen, amino, -NR6R7, alkyl of 1 to 12 carbon atoms optionally substitute...
|
|
WO/2006/085978A2 |
Fluorescent substrates for beta-lactamases having the general formula shown above are provided. Z includes a fluorophore or chromophore and includes a group that may link to the lactam-containing group; R1 and R2 are independently select...
|
|
WO/2006/084368A1 |
This application describes fluormated (+)PHNO and analogs thereof, including radiolabeled analogs, of Formula (I), wherein R1 is C1-6 alkyl in which one hydrogen atom on the alkyl chain is replaced with fluoro or radioactive fluoro. The ...
|
|
WO/2006/083271A2 |
The invention provides certain acylthiourea derivatives and pharmaceutically acceptable salts thereof. These compounds possess potent antiviral activity. The invention particularly provides compounds that are potent and/or selective inhi...
|
|
WO/2006/082495A1 |
The present invention relates to novel acetic acid derivatives as peroxisome proliferator activated receptor (PPAR) modulators. Compounds described herein can be useful to inhibit or prevent diabetes or diabetes associated complications ...
|
|
WO/2006/080284A1 |
Disclosed are a 2-substituted imino-1,3-oxazine derivative having a cannabinoid receptor agonist effect, and a pharmaceutical composition containing such a compound as an active constituent. Specifically disclosed is a compound represent...
|
|
WO/2006/079720A1 |
The invention concerns compounds of formula (I) and their use as hypoglycaemic or hypolipidemic agents
|
|
WO/2006/077025A2 |
The present invention refers to chemical compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in claim 1. These compounds can be used for the preparation o...
|
|
WO/2006/074798A1 |
Compounds of the formula (I): in which A, R1, R2, X, Y and Z are defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the...
|
|
WO/2006/070878A1 |
It is intended to provide a compound which has an anticoagulant effect based on the inhibition of the activated blood coagulation factor VII and, therefore, is useful as a blood coagulation inhibitor or a preventive/remedy for diseases c...
|
|
WO/2006/067587A2 |
This invention relates to biaryl ether derivatives of formula (I), wherein R1, R3, R4, X, W, Y and m are defined in the description, and to compositions containing them and the uses of such derivatives. The compounds of the present inven...
|
|
WO/2006/063821A1 |
The present invention relates to a method of preparing N-substituted salicylamides or derivatives thereof, and their salts, hydrates and solvates. In particular, the present invention relates to a method of preparing N-(5-chlorosalicyloy...
|
